Every 424B that Lexicon Pharmaceuticals, Inc. (LXRX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow LXRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LXRX filings page.
Lexicon Pharmaceuticals is offering 32,000,000 shares of common stock at $1.30 per share in a primary underwritten sale. Underwriters have a 30‑day option to buy up to 4,800,000 additional shares.
Affiliates of Invus, L.P., the largest stockholder, will buy 22,400,000 shares in a concurrent private placement at the same price, and are also purchasing two tranches of non‑voting convertible preferred stock at $65.00 per share that will convert into common stock on a 50‑to‑1 basis after shareholder approval to increase authorized shares and other conditions are met.
Lexicon expects net proceeds of approximately $79.9 million from the offering and the common stock private placement, or $91.9 million if all options are exercised, excluding additional net proceeds from the extra preferred shares. Funds will support continued research and development of its drug candidates, working capital and general corporate purposes. The company reported unaudited year‑end 2025 cash, investments and restricted cash of $125.2 million and a $10 million milestone from Novo Nordisk, with potential for up to an additional $20 million in 2026.
Lexicon Pharmaceuticals plans an underwritten public offering of common stock, together with a concurrent private placement to an affiliate of its largest shareholder, Invus, L.P., at the same price as the public deal. The Invus affiliate may instead receive convertible preferred shares if authorized common shares are insufficient, with those preferred shares expected to convert into common stock after shareholder approval of additional authorized shares.
Lexicon expects to use net proceeds from the offering and private placement to fund research and development of its drug candidates, including sotagliflozin and pilavapadin, and for working capital and general corporate purposes. The company recently reported unaudited year-end 2025 cash, investments and restricted cash of $125.2 million and a $10 million milestone from its Novo Nordisk licensing agreement, with the potential for up to $20 million in additional milestones in 2026, which it believes can support planned operations into 2027. As of January 26, 2026, Lexicon had 363,466,277 common shares outstanding, and Invus and its affiliates held approximately 49.7%, giving them significant influence over governance and capital decisions.
Lexicon Pharmaceuticals launched an at-the-market offering of up to $75,000,000 of common stock through Jefferies as sales agent. No sales have been made to date. Jefferies will receive a 3.0% commission on gross proceeds, and net proceeds will be used to fund research and development and for working capital and general corporate purposes.
An affiliate of Invus, L.P., the company’s largest stockholder, may concurrently purchase shares to maintain its proportionate ownership in connection with sales under the program, but only after yearly issuances under the ATM exceed two percent of shares outstanding as of the prior December 31. Any such purchases would occur in a concurrent private placement at the same price as the public sales.
The common stock trades on Nasdaq as “LXRX.” The last reported sale price was $1.38 per share on November 5, 2025. Shares outstanding were 363,398,860 as of November 5, 2025; this is a baseline figure, not the amount being offered.